Pricing

Neurogene Inc (NGNE)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jonathan G. Drachman
Employees:
90
SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
206-732-2133
    Formally known as:
  • NEOLEUKIN THERAPEUTICS ORD SHS
Stock Split History
DateRatio
2023-09-25 1:5
2023-12-19 1:4
Neoleukin Therapeutics, Inc. develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available